Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 7, 2019

Primary Completion Date

September 12, 2022

Study Completion Date

January 30, 2023

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

lerodalcibep

PCSK9 inhibitor

DRUG

evolocumab

PCSK9 inhibitor

Trial Locations (12)

2193

Carbohydrate and Lipid Metabolism Research Unit, Johannesburg

7925

Division of Lipidology, Department of Medicine University of Cape Town, Cape Town

12000

Department of Medicine, Hadassah University Hospital, Jerusalem

35040

Ege University Medical School, Izmir

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

49100

Rabin Medical Center, Beilinson Hospital,, Petah Tikva

60201

NorthShore University Health System, Evanston

110002

G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi

Unknown

VMMC & Safdarjung Hospital, Delhi

CIMS Hospital Pvt. Ltd, Ahmedabad

Afyonkarahisar Health Sciences University, Afyonkarahisar

0586

Lipid Clinic, Oslo University Hospital, Oslo

Sponsors
All Listed Sponsors
lead

LIB Therapeutics LLC

INDUSTRY